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Introduction: 
Schizophrenia (SZ) remains one of the least understood mental disorders despite 
extensive study. Efforts to better characterize the illness have led to advancements in 
nosology and classification of sUbtypes through clinical observation and research. The 
clinical manifestations of the illness are hypothesized to originate as abnormalities in 
brain structure and function which are in turn hypothesized to be the expressions of gene 
variants. Since the classification system used for diagnosis is based on clinical 
representation rather than pathophysiological etiology, subtyping by modern diagnostic 
criteria (e.g., Diagnostic and Statistical Manual for Mental Disorders) may be incorrect, 
or at least inexact, which may obscure attempts to accurately differentiate population 
groups. Given the complex heterogeneity of SZ, improved nosology may contribute 
substantially to proper diagnosis. 
The principles of psychiatric epidemiology are particularly useful when 
attempting to reconceptualize the nosology of psychosis because they provide 
information necessary to significantly improve the validity of the diagnostic systems. 
The clinical course of schizophrenia has been well documented but epidemiological study 
of pathophysiological markers is lacking. Advancements in vivo neuroimaging during 
the past few decades have allowed for extensive study of the brain both structurally and 
functionally and support the role of distributed aberrations of brain morphology in the 
etiology and expression of schizophrenia. Psychiatric epidemiology plays a pivotal role 
in improving our understanding of the brain variations detected in individuals with 
schizophrenia. Specifically, epidemiological study of pathophysiological traits in large, 
representative populations will determine the existence of and rates for phenotypic 
subtypes of neurophysiology. Simultaneous assessment of clinical symptomology and 
cognitive expression with these pathophysiological traits will allow for multifactorial 
patterns to emerge, thereby bridging the gap between pathophysiology and clinical 
manifestation. Thus, psychiatric epidemiology lies at the forefront of improving the 
nosology of SZ and the many efforts which employ this nosology. 
In light of the inherently physiological etiology of the disorder, I assert that there 
is great potential to reassess the diagnostic criteria and current subtyping systems using 
biological paradigms. In the final chapters, I apply a novel technique for identifYing 
natural patterns of structural variation in patients and discuss the potential for such 
research to detect more homogeneous subgroups which could lead to more valid 
diagnostic criteria. 
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CHAPTER 1: Epidemiology of Schizophrenia 
Psychiatric epidemiology is the study of rates of mental illness and associated 
factors which impact onset, course and outcome. It relies on the descriptive and analytic 
principles of epidemiology to provide substantive information that can be utilized in a 
variety of clinical, research, public health, and community settings. The first psychiatric 
epidemiology study was a census of the "insane" in the 1840 (1). Rudimentary compared 
to the field today, the census was the first effort to define rates of mental illness in the 
population. As a scientific discipline, psychiatric epidemiology differs from standard 
psychiatry in its emphasis on epidemiological and biostatistical concepts in the 
classification and nosology of psychopathology rather than the diagnosis and treatment of 
individuals. 
One of the first to strongly embody epidemiological principles in the study of 
mental illness was Emil Kraepelin. As part of his extensive work to classify mental 
disorders into different categories, Kraepelin, in 1893, was the first to draw a distinction 
between what he termed dementia praecox and other psychotic illnesses. He focused on 
patterns in cause, symptomology, course, final stage, and pathological anatomical 
findings when defining this diagnostic classification (2). In 1911, Eugen Bleuler coined 
the term' schizophrenia' in response to the misleading use of the term dementia. By this 
time, interest in the clinical syndrome had taken root. Between the late 1800's and mid-
20th century, epidemiological study of schizophrenia flourished. European researchers 
studied large populations for incidence and prevalence of mental disorders with special 
attention to heredity (3). Their extensive studies resulted in information on population 
incidence, prevalence, age at onset curve, age- and sex-specific morbid risk, and 
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morbidity risks for biological relatives of a schizophrenic proband (3) which remain 
consistent with current estimates. Americans focused on the social ecology, or correlates 
and risk factors, of psychosis (3). Demographic characteristics, innate factors that could 
be either predisposing to psychosis or protective from it, and environmental factors, such 
as nurturing style, were three major areas of interest (4). Although sl ight variations in the 
concept and classification of SZ occurred over the past century, the epidemiology of the 
illness has remained remarkably consistent (5). 
Clinical Phenotype 
Schizophrenia is characterized by a variety of symptoms that are traditionally 
organized into two categories. Positive (psychotic) symptoms represent aberrations of 
mental processing such that normal functions are distorted or in excess (1). They include 
hallucinations, delusions, disorganized speech/thought, and disorganized/catatonic 
behavior. Negative symptoms refer to a diminution or loss of normal function and 
include alogia, affective blunting, and avolition (1). Although not explicitly defined as 
symptoms in the diagnostic criteria, cognitive deficits are a major component of the 
illness that underlie the impairment in social and occupational function that is required 
for the diagnosis of SZ. Patients with SZ, on average, experience impairments in 
neurocognition in the order of 1.5 to 2 standard deviations below normal controls on tests 
of language, executive function, memory, attention, and motor processing (6, 7). 
Cognitive deficits are the most disabling symptoms of SZ in terms of leading a normal 
life (8). 
With the heterogeneity of the symptoms in SZ, several subtypes are used to 
further characterize patients with the illness (1). Paranoid subtype refers to patients 
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whose cardinal features are delusions and auditory hallucinations. These psychotic 
symptoms are often paranoid and persecutory in nature. Paranoid is the most common 
subtype. Disorganized subtype, also termed Hebephrenic, refers to patients whose 
behavior is characterized by incoherent speech, behaviors inappropriate to the situation, 
or other behaviors that indicate confusion. Catatonic subtype refers to patients who are 
socially and emotionally withdrawn and have marked psychomotor disturbance. The 
Residual subtype categorizes those patients who are no longer actively psychotic but still 
experience symptoms. Unditferentiated subtype serves as a catchall for patients who do 
not conform to the previous four subtypes or to patients who display features of more 
than one subtype without a clear predominance for a single type. 
Incidence and Prevalence 
Lifetime prevalence of schizophrenia generally has been cited at one percent of 
the population. The most recently published prevalence rate for non-affective psychosis 
over the lifetime in the United States was 5.0 per 1000 population (9). Other current 
studies which utilized representative community samples in both the United States and 
Israel estimated lifetime and 6-month prevalence rates at 0.7% (10, 11). Differences in 
reported rates over time are hypothesized to reflect changes in diagnostic criteria rather 
than a changes in disease prevalence. These include changes in the criteria for diagnosis 
of SZ or differences in the methods used to ascertain or identify patients (4, 5). Incidence 
rates are available from 16 countries sampled for the World Health Organization (WHO) 
Determinants of Outcome of Severe Mental Disorders study and a review of European 
countries by Jablensky (12). Both sources cite incidences of schizophrenia at 
approximately 0.2 per 1000 population (4). While some communities may demonstrate 
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substantially higher prevalence rates for indigenous reasons, schizophrenia appears in 
similar rates throughout the world (5, 13). 
Demography 
Onset of schizophrenia usually occurs in late teens and early twenties, with some 
severe cases presenting with earlier onset in the mid-teens. Onset is preceded by a 
prodromal phase which lasts, on average, 5 years (14) during which less severe traits of 
the disorder are present. Onset for women occurs approximately 5 years later than for 
men (13). Differences in prevalence rates between the sexes are cited by some to be non-
existent (15) while others claim a 2-fold increase in males (13). Differences in perceived 
rates may be attributed to sex differences in expression of the disease. Females tend to 
show less severe psychopathology which may reduce occasions that require clinical 
contact (16). For example, females tend to have better premorbid functioning, less 
disability, and higher percentage of remitting course (17) although symptomology 
is very similar (15). As discussed earlier, 5Z appears to occur at comparable rates 
in many cultures and races (5, 13), however racial differences in cultural norms 
or racial disparities in healthcare access can impact diagnosis and treatment (10). 
Heredity/Genetics 
Early studies of mental illness recognized the tendency for psychosis to 
run in families (3). Contemporary studies of heritability demonstrate significant 
increases in rates of the illness as the amount of shared genetic information 
increases. Compared to the baseline risk of 1 % in the general population, 1st 
degree relatives (siblings) have a 9% risk of developing the illness and children 
of parents who both have schizophrenia (full genetic loading) show a risk of 
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about 46% of developing the illness (18). Twin studies provide further support in 
that fraternal (dyzygotic) twins of affected individuals show a rate of risk similar 
to other siblings while identical (monozygotic) twins show a risk of almost 50% 
of developing the illness if the co-twin is affected (19). Adoption studies 
demonstrate that the disease is more than a function of environment. 
Schizophrenia twins or offspring of schizophrenic parents adopted away from 
the schizophrenic environment still show increased risk while children adopted 
into schizophrenia families do not show increased risk for the disease (20). 
Alternatively, the influence of environment is reinforced by the fact that identical 
twins show at most a 50% risk if the co-twin is affected. Specifically, geneticists 
have calculated that approximately 70-80% of the liability for schizophrenia is 
genetic while 20-30% is environmental (21-23). While 70-80% of the liability is 
estimated to come from genetics, the 20-30% of liability attributed to 
environmental factors may translate into a much greater that 20-30% influence on 
expression. The fact that individuals with a genetic liability for the disease are at 
significantly increased risk compared to the general population but still have at 
most a 50% chance supports the theory that what is inherited is a predisposition to 
developing schizophrenia (21). 
Social Burden 
Marked by debilitating mental function, people with schizophrenia have long 
periods of illness, are unable to work, and have difficulty in sustaining family 
relationships (21, 24) causing major strain for those who care for them (24) and society in 
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general (13, 25, 26). Although patients vary in course and outcome, the majority require 
psychiatric, community, or social services for the duration of their lives (27). For 
instance, a review of the literature on course and outcome suggested that "21 % to 57% of 
individuals achieve a relatively good outcome, whereas others continue to have 
significant impairment" (28). This dependence on others combines with early onset and 
poor outcome to become the 2nd ranked mental illness for the global burden of disease 
based on 2.3 million years of potential life lost due to premature mortality or due to loss 
of productivity resulting from disability (25). Given the level of required care and 
treatment services and the chronicity of the illness, it is not surprising that the direct costs 
of schizophrenia exceed those of unipolar depression (29). In 1990, the direct cost of 
treating individuals with schizophrenia totaled 17.3 billion, or about 53.2% of the total 
expenditures for hospitalization, treatment and rehabilitation, and lost productivity of 
32.5 billion (29). 
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CHAPTER 2: Diagnostic Nosology 
Kraepelin postulated that psychiatric diseases are principally caused by biological 
and genetic disorders. He believed that the natural patterns of the clinical 
syndromes could provide a provisional measure of validity of the disease concept 
until final verification could be achieved by establishing brain pathology and 
etiology (2, 3). Both Kraepelin and Bleuler emphasized that schizophrenia was a 
disorder in which a morbid fragmentation of cognitive processes developed 
unusually early in life (30). The terms" dementia praecox" and" schizophrenia", 
chosen separately by these scientists, reiterated this conceptualization. The 
severity and variety of symptoms associated with schizophrenia were not 
considered to be the defining traits. Positive symptoms, for example, were 
recognized to occur in a number of other psychiatric disorders mitigating any 
specificity to schizophrenia. Rather, Kraepelin "saw the diversity of symptoms as 
unified by the underlying destruction of cognitive processes" (31). Kraepelin's 
systematic investigations of the symptoms, course, outcome and correlates of 
schizophrenia were aimed at improving the conceptualization of the illness and 
compensated for limited capacities for pathophysiological study. His precocious use of 
the principles of psychiatric epidemiology were remarkably comparable to modern 
scientific psychiatry and his classifications served as the foundation for the modern 
nosological systems in use today (2, 3). 
A marked divergence between Kraepelin's work and modern diagnostic systems 
is the attention to non-clinical factors. Coinciding with the increasing awareness of 
schizophrenia, the first half of the 20th century experienced a dramatic expansion in 
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psychiatric and medical research on an international level (3). Bourgeoning needs for a 
unified psychiatric nomenclature led to the development of the first Diagnostic and 
Statistical Manual: Mental Disorders (DSM-I) in 1952 which focused on clinical utility 
rather than the coding of disease which was provided by the International Classification 
of Disease (1). In 1980, the third version of the Diagnostic and Statistical Manual of 
Mental Disorders was published. The DSM-III was developed to serve as a guideline for 
establishing universal and reliable psychiatric diagnoses using the manual's explicit 
diagnostic criteria, a multi-axial system, and descriptive approach (1). The nature of this 
classification system demanded that a particular psychiatric disorder be delineated by its 
observable behaviors or symptoms. The goal was to provide a reliable, clinical guideline 
for the field of psychiatry such that formally trained clinicians could use the manuals as a 
reference but not a finality when making diagnoses (2). As the versions of the DSM 
developed so did dependence on the manual for communication, education, and training. 
The DSM became a textbook rather than a guideline and the skill of diagnosis was often 
replaced by a checklist of symptoms (32). This is particularly true with researchers in 
psychiatry, neuroscience, and epidemiology who applied the diagnostic criteria rigidly, 
often without formal clinical training. In reference to schizophrenia, conceptual shifts 
throughout the century refocused attentions toward the symptoms associated with the 
disorder, particularly positive symptoms, and were reflected in the DSM by concomitant 
shifts toward positive symptoms in the criteria for diagnosis (33, 34). Despite the fact 
that both Kraepelin and Bleuler emphasized that the disorder was not defined by clinical 
symptoms (31), current diagnostic classification systems use symptom constellations to 
diagnose schizophrenia. 
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Modem diagnostic classification systems may have sacrificed validity for the sake 
of reliability (35). Attempts over the last 100 years at finding a test, any test, which can 
give a deterministic diagnosis of SZ have been unsuccessful. It is quite possible that 
these failures are due, in part, to the invalidity of symptom-based assessments for 
diagnosis and the failure to incorporate the biological principles of schizophrenia in the 
study of the disease. The DSM-IV addresses the limitations of its categorical system, 
stating that "a categorical approach to the classification works best when all members of 
a diagnostic class are homogeneous, when there are clear boundaries between classes, 
and when the different classes are mutually exclusive" (I). In the case of SZ, none of 
these conditions is met. In tune with the modem conceptual shifts that emphasize 
biology and genetics in the development of psychiatric diseases, diagnostic classification 
systems that utilize a "definition of the phenotype ... that is heuristic for studying 
mechanisms of the illness" (31) may greatly improve both the validity and reliability of 
the diagnoses. The current diagnostic system with its dependence on descriptive 
psychopathology creates a divide between the goals of clinicians and the goals of 
researchers. For an effective transition of information between fields, clinicians and 
researchers need to utilize the same constructs. 
Compilation of the original diagnostic manuals occurred prior to the emergence of 
extensive scientific study in neuroscience, pathophysiology, and genetics. Research over 
the past two decades in each of these fields has imparted unique contributions to 
conceptualization of the etiology and presentation of the illness. With advancements in 
science and technology, it is now possible to test whether schizophrenia, as postulated 
by Kraepelin, is an expression of altered brain pathology and to reformulate the 
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diagnostic criteria for schizophrenia to encompass the nature of the illness as a 
fragmentation of the mind while still lending itself to both clinical application and 
scientific study. Psychiatric epidemiology lies at the forefront of this endeavor. Before 
an improved nosological system can be created, the foundation for the system must be 
established. "The acceptance of a particular diagnostic concept or a classification scheme 
is usually based on the interpretation of converging evidence from multiple sources, 
including descriptive psychopathology, neuropathology, pathophysiology, genetics, and 
epidemiology" (3). The study and treatment of SZ would benefit greatly from an 
itillovative epidemiological perspective which seeks to improve upon current diagnostic 
practice in each of these fields. 
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CHAPTER 3: Psychiatric Epidemiology of Neuroanatomy 
One of the most defining characteristics of schizophrenia as a disease concept is 
its complexity, both clinically and pathophysiologically. Interest in the illness has incited 
extensive academic pursuit evidenced by a overabundance of research reports over the 
past century. Based on these reports and clinicians' experience, several theories 
regarding the etiology of schizophrenia have evolved, often in parallel with secular trends 
and scientific/technological advancements. The 1990's, referred to as the 'decade of the 
brain', experienced substantial growth in in-vivo imaging as technological improvements 
in computerized axial tomography (CT), positron emission tomography (PET), and 
magnetic resonance imaging (MRI) combined with researchers' increased access to 
scanners. Psychiatric researchers, previously constrained by the limitations of post-
mortem assessments, now had opportunities to explore both structure and function in the 
living brain. Several theories about the etiology of schizophrenia as 
neuroanatomical in nature have been supported by these research findings. "Evidences 
from these studies have strongly demonstrated that schizophrenia is a chronic 
brain disorder, structurally and functionally affecting various cortical and 
subcortical regions involved in cognitive, emotional, and motivational aspects of 
human behavior" (36). As of yet, however, no single abnormality of brain 
structure has been found to be 'pathognomonic' for SZ (37). 
Two theories have prominently addressed the role of brain anatomy 111 the 
development of the illness. Andreasen's "cognitive dysmetria" theory proposes that the 
root of the disorder is a disruption of neuronal connectivity of the prefrontal-thalamic-
cerebellar circuitry which evokes the clinical manifestations (38, 39). Pearlson's 
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"heteromodal association cortex" theory asserts that schizophrenia is caused by aberrant 
network function due to structural impairments to brain regions that are uniquely 
'human'. such as the heteromodal association cortex (HASe) (40). Both theories 
recognize that schizophrenia is not the result of a single focal abnormality nor does it 
appear to be the result of pathological neural markers like those detected in Alzheimer's 
disease (plaques, tangles) (31, 41). The evidence of widespread, distributed anatomical 
aberrations supports the perspective that SZ results from disruption in neural circuitry, 
either anatomically or neurochemically (31, 37). 
Applying the principles of epidemiology to the study of psychiatric neuroscience 
creates many opportunities for innovative explorations of brain-behavior phenotypes. 
Epidemiology is a propitious next step in schizophrenia research espoused by several 
researchers in the field. Excerpts from two review articles are presented here: 
"In the 20th century the range of methodological and analytical 
tools available in psychiatric epidemiology was enormously 
expanded (Jablensky, this volume). Epidemiological research into 
the frequency, distribution and course of abnormal brain 
morphology (Jones et al. 1994), already underway, and the 
dawning epidemiology of functional anomalies and brain 
processes will be developed further on the neurobiological and 
psychological level" (42). 
liThe relationship between schizophrenia epidemiology and 
molecular genetics is considered to be one of incremental mutual 
support; the power of molecular genetic studies depends critically 
on the ability of epidemiological work to delineate homogeneous 
subgroups of the disorder in whom the share of genetic risk is 
assumed to be particularly large" (43). 
Specifically, two prime uncertainties can be addressed with the epidemiological 
study of neuroanatomy. One uncertainty addresses the conceptualization of the illness 
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itself. The heterogeneity in the expression of the illness has fueled long-standing doubts 
about the diagnosis of SZ representing a single disease entity or a mixture of various 
disease processes (35, 44, 45). Studying variations in clinical and anatomical phenotypes 
and their relationships with each other may reveal how aberrations in neuroanatomy 
manifest clinically. Jointly characterizing multiple phenotypic presentations may 
uncover the commonalities and differences of various subgroups of patients which 
provide insight into the validity of current subtypes and the disease process overall. 
Identifying both unique and common etiologies of brain structure and function is one 
promising approach to determining whether schizophrenia is a single illness with a broad 
spectrum or an amalgamation of several illnesses into one diagnosis. Thus, large scale 
studies of both clinical expression and pathophysiology using epidemiological principles 
are vital to the development of a revised taxonomy. 
The second uncertainty is whether neuroanatomy can be so well characterized 
that an individual can be reliably and validly diagnosed with schizophrenia based on 
neuroanatomical measurement. Variability in affected brain areas as well as variability 
in the severity of the morphological aberration can obscure attempts to discriminate 
patients from controls based on brain structure. In addition, aberrations in morphology 
occur along a continuum that overlaps considerably with normal controls and diminishes 
the ability to define 'abnormal'. These two inherent qualities of SZ continue to impede 
efforts to define distinct phenotypes. Scientific methodologies also have hindered efforts 
to distinguish anatomical phenotypes. Many research reports in psychiatric neuroscience 
employ small sample sizes (N<40) which undermine the success for detecting 
meaningful differences. Specifically, smaller sample sizes increase the likelihood for 
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type II errors, especially with the high variability in brain morphology in patients but not 
control subjects. Despite the fact that neuroanatomy is theorized to play an integral role 
in the etiology of SZ, few studies have assessed the ability for neuroanatomical measures 
to predict diagnosis and/or outcomes (28) perhaps for the reasons discussed here. The 
collection of large scale neuroanatomical studies that embody the principles of 
epidemiology may achieve new heights in the characterization of neuroanatomy on an 
individual level and foster interest in its predictive potential. 
Several epidemiological principles, in particular, have been lacking in the 
majority of modem research endeavors. First, as discussed above, small sample sizes 
inherently weaken the likelihood of detecting differences between patients and controls, 
limit the potential for detecting more uniform subgroups of patients, and limit the 
generalizability of the results. Large-scale studies, in the order of 100 or more per 
diagnostic group, can substantially reduce these limitations (see (46-48) for examples). 
Second, neuroimaging studies often require the comparison group to be both physically 
and mentally 'healthy' in order to reduce confounds and increase the likelihood for 
detecting differences. A population study of brain anatomy using community controls, 
not 'healthy' research controls, will provide a normative and generalizable 
characterization of brain morphology. The inclusion of other mental illnesses in the 
development of nomlative measures will allow for the emergence of aberrations that are 
specific to SZ and not to mental illness. Third, associations between patients' 
presentation and course and the patient's brain morphology are rarely tested. Exceptions 
to this are the growing number of researchers who attempt to correlate symptomology 
and/or neurocognitive performances with neuroanatomical measures. Patients' course 
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and outcome are intrinsic qualities of the illness which necessitate increased attention. 
The development of hypotheses a priori and the application of more advanced statistical 
tests (which will also be feasible with larger sample sizes) will help researchers capitalize 
on these variables. To recapitulate, "closer links between epidemiology and structural 
neuroimaging ... will enable us to further define structural abnormalities associated with 
each [psychiatric] disorder and their specificity" (49). 
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CHAPTER 4: Evidence of Structural Differences and their Clinical Correlates 
Identification of structural abnormalities in SZ has been a primary area of interest 
since the increased accessibility of in vivo assessment techniques. Reports of volumetric 
differences between patients and controls have been reported for most parts of the brain 
although this literature has been pray to inconsistent reports regarding the location and 
direction of volumetric differences. Several reviews attempt to summarize the vast 
literature on this topic and I refer you to them for a full understanding of the reported 
structural aberrations in SZ (see (37, 50) for reviews). In this chapter, I will comment on 
the most consistent and relevant findings. 
Chronicling the morphometric differences between healthy control subjects and 
persons with schizophrenia provides insight into where disruptions in normal functioning 
may occur. Associating a brain structure with an observable behavior creates a 
conceptual bridge that is important to cross when attempting to determine the role of 
structure in clinical expression and in the definition of subtypes. Evaluation of the 
existence of morphology-symptom and morphology-cognition associations increases our 
understanding of how numerous brain regions may synergize to create the heterogeneous 
clinical expression of SZ. "It is unclear if there are subgroups of SZ with distinct clusters 
of particular volume abnormalities that involve discrete neuroanatomic circuits" (37). 
Several morphometric studies of brain structure have found significant associations 
between regional brain volumes and severity of symptoms and cognitive performances. 
Relevant studies are included in the discussion of structural differences. 
For the purposes of this thesis, I will limit the scope of structural abnormalities to 
brain volumes. Structural assessments that involve shape, connectivity (e.g. diffusion 
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tensor imaging), or occur at a cellular level are beyond the purvIew of this thesis. 
Volumetric structural measurements will predominately come from MRI assessments. 
Differences between volumetric measurement tools, such as region of interest (ROI) vs. 
voxel-based morphometry (VBM), can introduce variability in findings. I give equal 
credit to reports using either methodology, however, for direct comparison of our 
findings to previous work, I will focus on prior VBM studies in the final chapters. 
Global Volumes 
Global brain volumes can be divided into 4 categories: whole brain, gray matter 
(GM), white matter (WM), and cerebrospinal fluid (CSF). Assessments of whole brain 
size in schizophrenia have not typically found significant size differences between 
patients and controls (51) but global GM has been found to be reduced in patients in the 
order of 2-4% (52, 53). Literature reviews that included WM have reported tendencies 
for both decreases (32) and increases (52). White matter increases may occur in 
proportion with GM decreases (52) offsetting any whole brain volume loss in patients 
with GM decreases. The ratio of gray to white matter within the brain has been 
suggested to be of interest, although no major findings have been repOlied. Pearlson and 
Marsh (1999) suggest that global volume reductions such as those seen with GM do not 
always reach statistical significance despite focal deficits of 10%-15% (37). 
Overall, global measures of brain volume have not been a fruitful area of study in 
schizophrenia research with the exception of cognitive function. Whole brain volume has 
a non-specific association with cognitive performances in both patients and controls (6, 
54-56). For example, Antonova (2005) reported smaller global GM volume correlated 
with lower premorbid IQ in patients but also in controls. Kareken (1995) reported that 
19 
deficit but not non-deficit patients had reduced whole brain volumes compared to 
controls. Since cognitive impairments are more severe in deficit patients, brain volume 
deficits may be a key element to understanding the clinical manifestations of select 
subgroups of patients. 
Ventricle,')-
Ventricular enlargement is a highly consistent finding in SZ. The ventricles are 
sub-divided into lateral, third, and fourth. The lateral ventricles are further defined with a 
frontal hom, body, occipital hom, and temporal hom. Lateral ventricular enlargement, 
especially in the temporal hom, has been well documented, as well as enlargement of the 
third ventricle (50) while the fourth ventricle has not shown enlargement in patients. 
Pearlson and Marsh (1999) remark that it is difficult to determine if increased ventricular 
size is itself an anatomic abnormality or if it is a proxy for changes in neighboring brain 
structures (37). Enlargement of the temporal horns may reflect GM reductions in the 
temporal gyri (50) and enlargement of the third ventricle may relate to the reported 
reductions in thalamic volume (57). It is important to note that despite the consistency of 
enlarged ventricles in SZ, ventricular enlargement is commonly found in a variety of 
other psychiatric and non-psychiatric conditions (37), thereby minimizing the 
contribution of this abnormality to the isolation of schizophrenia's etiology. A recent 
study of the heritability of ventricular size suggested that genetics have a stronger 
influence over ventricle size than schizophrenia-related changes (58) further supporting 
an indirect association between ventricle size and schizophrenia. 
Studies testing the correlations between cognition and ventricular size have failed 
to find consistent associations in patients, although studies utilizing ventricular-to-brain 
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volume ratios have been more reliable (6). Enlargement of ventricles may be a non-
specific indicator of decreased brain tissue for which more localized assessments of tissue 
volume correlate better with cognitive measures. 
Temporal lobe 
The temporal lobe is comprised of 1) the superior temporal gyrus which includes 
the primary (Heschl's gyrus) and secondary auditory cortices and the planum 
temporale, 2) the middle and inferior temporal gyri, and 3) the medial temporal 
structures of the limbic system. Smaller volume in the superior temporal gyrus (STG) 
of the temporal lobe is the most robust finding for a focal region in SZ research (59) and 
is principally GM in origin (50). Volume loss in the STG is also highly specific to SZ 
unlike the ventricular volumes noted above (37). Reports for volume changes in the 
middle or inferior temporal gyri are less consistent (60,61). 
The role of the temporal lobe in processing sensory inputs, speech and 
language has incited extensive interest in the relationship between temporal 
structure and function and the existence of auditory hallucinations, delusions, 
and impaired language(61). Numerous studies have studied the associations 
between structure and clinical symptoms with promising results. For positive 
symptoms, GM volume loss in the STG, in particular, has correlated with 
hallucinations (28, 62-64) and formal thought disorder (60, 64-66) but not with 
delusions (28). Negative symptoms have also correlated with temporal lobe 
volume loss (67, 68). Neuropsychological performance in a variety of cognitive 
domains have positively correlated with temporal or STG volume in patients (65, 
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69-72) although some studies have not shown associations (6, 73). 
The Planum Temporale (PT) is a discrete region of the posterior STG which is 
believed to be the "neural substrate of language" (50, 74). The PT displays a discernible 
left greater than right asymmetry in the normal population that is diminished in patients 
with schizophrenia (75-80). The disrupted asymmetry is attributed to enlarged right PT 
volumes and/or left PT reductions (77, 78, 81, 82). Pearlson (1996, 1997) suggests that 
the PT is a primary ROI in the structural basis of SZ (40, 61) for which anatomical 
aberrations have yet to be identified in any other psychiatric disorder (40, 50). Although 
the PT is a portion of the STG which has been heavily correlated with symptomology, the 
PT as a discrete sub region of the STG has also correlated with thought disorder (65, 66, 
82-84) and higher scores on the suspiciousness/persecution subscale of the Positive and 
Negative Symptom Scale (78). 
Medial Temporal Lobe 
The medial temporal structures are the amygdala, hippocampus, and 
parahippocampal gyrus. These structures, also known as the limbic system, mediate 
emotion and memory and are implicated as aberrant in SZ based on the observation that 
memory is one of the most marked impairments exhibited in schizophrenia (6). 
Early post-mortem studies reported tissue loss in these medial regions (50) 
followed by MRI studies reporting reductions in the amygdala-hippocampal complex 
(83), amygdala alone (53, 69, 85), hippocampus alone (53, 69, 85), and parahippocampal 
gyrus (53) in SZ both in chronic and first episode patients (36, 59, 68). Volume in limbic 
structures have been positively correlated with thought disorder (83), symptom severity 
(37), and negative symptoms (68). Results of studies relating performance on memory-
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related tasks to medial temporal lobe volumes in patients have been mixed: several report 
positive correlations (70, 86-88) while others report no association (86, 87, 89) depending 
on the structure and the memory task being assessed. No studies that assessed medial 
temporal volumes and cognition found an association between parahippocampal gyrus 
volume and cognition in controls suggesting a specificity of the parahippocampal gyrus 
to cognitive functions in SZ (6). 
Frontal lobe 
Frontal lobe dysfunction is considered to be an important cause of the specific 
abnormalities of cognition and behavior that are commonly seen in SZ (6, 38, 40). 
Conventionally divided into the superior, middle, inferior, medial, and orbital gyri, the 
frontal cortex is highly connected with every other cortical structure in the brain (90). 
The frontal cortex is also a significant part of neural circuitry and a number of 
cortical-subcortical networks evidenced by reciprocal connections to all other 
areas of the cortex, as well as to limbic and basal ganglia structures (91, 92). 
While reports using whole lobe volume measurements have been inconsistent, recent 
parcellation studies of prefrontal subregions have reported specific volume reductions in 
discrete areas including the inferior, middle, and orbital gyri, and dorsolateral and 
dorsomedial regions (6, 36, 50, 59). Frontal lobe volumes have correlated with both 
positive (62) and negative symptoms (68, 93) but not as robustly as the temporal lobe. 
On the other hand, impaired cognitive performance and frontal lobe reductions 
have been well documented. Irrespective of volumetric differences between patients and 
controls, several studies have reported significant relationships between volumes in the 
frontal lobe and performance on cognitive measures-particularly on tasks that engage 
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the frontal cortex (executive functioning, working memory, verbal fluency, immediate 
memory) (6, 7, 3 L 54, 59, 70, 94). Variability in the existence of and associations 
between cognitive deficits in frontal function and volumetric deficits in the prefrontal 
cortex indicate that abnormalities in other brain regions may impact frontal functions (6) 
and that there may be select subgroups of patients who present with disruptions in either 
neuronal circuitry or anatomy. 
Parietal lobe 
The parietal lobe is comprised of the post-central gyrus, superior parietal lobule, 
and inferior parietal lobule. Although the parietal lobe has not been a major ROI in 
investigating volume abnormalities in SZ, the supramarginal and angular gyri that 
constitute the inferior parietal lobule (IPL) are critical parts of the heteromodal 
association cortex (40, 92, 95). Located close to the PT, the IPL is hypothesized to be 
involved with language development and comprehension (40, 91, 95). The IPL is also 
implicated in visuospatial processing, visual working memory, and attention (50). 
Similar to the PT, the IPL shows a left greater than right asymmetry in normal subjects 
which is important for normal language development (50, 96). Of the few studies that 
have assessed subregions of the parietal lobe in schizophrenia, volume or GM density 
reductions were reported for the supramarginal gyrus (85, 97) and IPL (98, 99). Further, 
there was reported reversal of the left greater than right asymmetry in the angular gyrus 
in males and in the supramarginal gyrus (50, 100, 101). 
Exploration of the association between symptoms or cognition in SZ and parietal 
lobe size is minimal. Sullivan (1996) reported no significant differences in parietal or 
parietal-occipital volumes between male patients and controls nor did they find 
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significant correlations between parietal volumes and cognitive functioning in 4 domains 
(executive, verbal, memory, motor). Antonova (2004) suggests that the global 
measurement of the parietal region may have negated the detection of associations with 
cognitive functions given the differences in functionality for subregions of the parietal 
and occipital region. Bilateral parietal lobe volume reductions were found to be 
associated with the auditory oddball fMRI task in schizophrenia, using joint independent 
component analysis (102). 
Cerebellum 
The cerebellum has been implicated as a ROI in SZ because of its role in a variety 
of motor tasks (neuromotor function is often irregular in SZ), connectivity with cortical 
and limbic structures, and role in cognition (30, 38, 50). Decreased cerebellar volumes in 
patients compared to controls are typically found (38, 73, 99, 103); increased volumes 
(104) but the reports of correlations to symptoms are lacking. Bottmer (2005) found 
smaller cerebellar volumes in patients inversely correlated with soft signs but showed no 
relation to clinical course (105) while Szeszko (2003) reported a lack of association 
between cerebellar volume and overall cognition in patients that was evident in healthy 
controls (106). Smaller cerebellar volumes were associated with neuromotor 
abnormalities which were in turn (but not directly) associated with poorer cognition and 
more severe symptomology (107). Associations of cerebellar volumes with cognitive 
functions were found for controls and affected women but not affected men (6). Further 
research is needed to clarify the associations of cerebellar structure with clinical 
presentations. 
Thalamus 
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Known for its role as a major relay station in the brain, the thalamus is responsible 
for much of the communication between cortical areas by modulating the incoming 
sensory information and outputting information to other cortical areas. It has been 
implicated specifically in attention, information processing, and gating (50) and has 
reciprocal connections with a variety of brain structures as evidenced by the delineation 
of several cortical circuits that involve the thalamus (108-112). Thalamic explorations 
have been thwarted by the difficulties in reliable delineation of the structure using MRI. 
While several groups have reported decreased thalamic volumes, others have reported no 
differences between diagnostic groups. Even with improvements in imaging technology 
and assessment/quantification methods (113), recent studies continued to report mixed 
findings regarding volume reductions in patients (73, 99, 114-116) but often report 
correlations with other regional brain volumes (57, 113, 117), symptoms (118, 119), and 
illness course (120-123). 
Basal Ganglia 
The Basal Ganglia (BG) is comprised of the caudate, putamen, and globus 
pallidus. The caudate and putamen are often referred to as the striatum. Each structure 
of the basal ganglia is differentially involved in cognitive, sensory, and motor processing 
(124). Volumetric studies of the BG via MRI have typically reported increases (125, 
126) although there is growing evidence for the confounding of BO size from atypical 
neuroleptics (6, 127, 128). In studies of drug-nai"ve patients, caudate volumes were found 
to be no different (128) or decreased (50, 127) compared with controls. 
A handful of studies have explored associations between BG volumes and clinical 
manifestations. Sigmundsson (2001) measured numerous brain regions in patients with 
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enduring negative symptoms and reported that these patients had increased BG GM 
volume compared to controls which positively correlated with positive symptoms. 
Buchanan (1993) reported a trend for deficit patients to have larger right caudate volumes 
(118). Spinks (2005) reported that volume of the extemal segment of the globus pallidus 
was correlated with severity of global symptoms although there were no volumes 
differences between patients and controls (129). Two studies reported an inverse 
relationship between volumes in BG structures and cognitive flexibility/abstraction (123, 
130). 
It is important to note that there are a number of factors which can confound, or at 
least complicate, detection of structural differences in schizophrenia, such as sex, age at 
assessment, age at onset, course, medication, treatment regimens, diagnostic criteria, and 
comorbidities (36). Although the majority of studies comparing patients to controls 
attempt to match for age and sex on a group level, the potential for additional 
confounders creates the need for continued study of brain structures, preferably with 
larger samples sizes and well characterized patient groups. One of the largest obstacles 
in studying correlates of schizophrenia is that the range of a particular construct usually 
overlaps considerably with the normal population (37) which prevents the ability to 
demarcate a point or line for abnormality. Improved characterization of brain anatomy in 
normal population groups can help define size, shape, variability, patterns and 
intercorrelations of brain regions. 
There are several limitations ofthe studies associating cognition to brain volumes. 
One is the variability in measures and interpretation of measures used to assess cognitive 
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domains, as well as the lack of attention to construct validity (6). Another is equating the 
level of difficulty to that of controls; it can be difficult to determine whether poorer 
performance is the result of smaller volumes, overall impaired neuronal networks and 
circuitry, or inequality in cognitive load (6). 
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CHAPTER S: Alternative SUD(J!ping 
Past efforts to define subgroups of schizophrenia that do not conform to the 
criteria set forth in the DSM-IV have been fueled by salient issues. Subgrouping patients 
based on neuropsychological function (131-133), familial or sporadic (134, 135), course 
and outcome (136, 137) or symptom presentation (135, 138-141) strive to identify 
homogeneous subpopulations that may be more conducive to exploration of biological 
etiologies. Second, these subgroups may address lingering concerns over the validity of 
the current diagnostic subtypes and SZ as a single unified pathological process. In 
addition, sub setting patients based on positive responses to certain medications and 
exploring associated factors may improve treatment regimens (142), essentially using 
evidence based practices. However, alternate subtyping in SZ is defunct if no additional 
information can be gleaned from the revised classification. Although there are a 
number of concerns over the validity of current diagnostic subtypes and there 
have been a number of attempts to define alternative subtypes, only a few have 
been examined for biological or phenotypic correlates (34). 
Leonhard's classification of SZ subtypes is one alternative that has been 
studied for a variety of disease correlates. Leonhard subdivided schizophrenia into 
three subtypes based on different types of symptomology, long-tern1 course, and clinical 
outcome: systematic schizophrenia, unsystematic schizophrenia, and cycloid psychosis 
(36). Several researchers have utilized these subtypes in their studies with promising 
results. Systematic SZ had significantly more maternal gestational infections during 
pregnancy and significantly more obstetric complications than unsystematic SZ or 
controls (143). Differences in P300 topographies and latencies between Leonhard's three 
29 
subtypes have been reported (36). Genetic studies have reported different genetic 
backgrounds between the subtypes; for example, systematic catatonia is usually sporadic 
not familial (144). A recent MRI study that used both DSM-IV and Leonhard's 
classifications reported significant aberrations in brain morphology for Leonhard's 
systematic SZ compared with controls but not for non-systematic forms or for any of the 
DSM-IV subtypes (145). Thus, alternative subtypes show promise for detecting 
associations with a variety of physiological correlates that have not been accomplished 
using DSM-IV subtype classitications. 
There is also great potential for biological endeavors to suggest more 
homogenous phenotypes. Reporting that a substantial subgroup of patients showed 
ongoing cerebral degeneration, Knoll proposed that a degenerative type of SZ may exist 
and that this subgroup is similar to the intellectually deteriorated subgroup of patients 
defined using neuropsychological testing (36). Pearlson and Marsh (1999) also 
acknowledge that cerebral degeneration may be limited to a subset of patients, notably 
the Kraepelinian subset (37). Sponheim (2001, 2003) explored whether biological 
measures known to be deviant in psychosis could discriminate patients from controls 
(146, 147). Sponheim et al. measured ocular motor functioning, electroencephalogram 
frequency characteristics, nail fold plexus visibility, and electrodermal activations in 5 
study groups: patients with SZ, 1 st degree relatives of patient with SZ, patients with 
affective disorder, 1 st degree relatives of patients with affective disorder, and non-
psychiatric control subjects (146). The authors compared the sensitivity and specificity of 
each measure in differentiating diagnostic group pairs. Three out of four of the biological 
measures significantly differentiated SZ patients from non-psychiatric controls. One of 
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these measures also significantly differentiated SZ patients from atlective patients. 
Although Sponheim's predictive values werc modest, the potential to tap the predictive 
ability of biological phenotypes has been considered. Additional statistical methods such 
as principal components, principal factors and cluster analyses may also advance the 
delineation of biological subtypes. Future studies should employ more efforts to 
capitalize on biological indices known to be affected in psychosis. 
Beno/its and LimilatiOllS qf Sub(ypillg Structural Dilforences and their Cililical 
COITelates 
Patterns of brain morphology are biological markers, or endophenotypes, which 
are traits that covary with an illness without being causative agents. Brain morphology 
represents a halfway point between the genetic/environmental etiologies and the varied 
clinical presentations (148). As such, these markers are likely to associate with both 
etiology and expression thereby bridging the gap between cause and effect. 
"Th[ e] clinically observed presentation of schizophrenia may not in fact 
represent the true phenotype, since it is comprised of varied symptoms 
that derive from diverse systems, occurs in non-overlapping patterns, and 
does not breed true. Instead, the phenotype may perhaps be best defined 
by a process that lies behind the symptoms, or a metaprocess, sometimes 
also referred to as an endophenotype, which is a 'final common pathway' 
that defines the illness." (31) 
The use of brain endophenotypes as markers for schizophrenia has a number of 
advantages in the search for schizophrenia etiologies. Brain structure is more tangible 
and less state dependent than clinical symptomology allowing for bettcr quantification 
and classification of affliction. Brain structure is measurable for the entire popUlation, 
allowing for mapping of risk across the general population and the potential for 
identifying de novo/isolated incidences of schizophrenia (21). Discrete structural 
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aberrations may produce specific clinical manifestations which can lead to 
pharmacological treatments designed to target the specific abnormalities as well as an 
improved understanding of the relationship between brain structure and function. There 
is the potential for data-driven techniques, such as factor or cluster analyses, to provide a 
starting point for exploring whether brain patterns do exist and how they relate to clinical 
presentation. Two main limitations common to SZ research still remain. Brain sizes and 
shapes occur on a continuum with no set point of abnormality. Any demarcation made 
by researchers would, at this time, be arbitrary. Anatomical structure varies extensively 
from patient to patient (more so that in the general population) with some patients 
expressing gross morphological abnormalities. Variability in morphology of numerous 
structures complicates the discrimination of structures that impact the illness from 
structures that do not impact the disease process. 
Previous Attempts to D¢ne Stmctural Subtypes 
Previous attempts to define structural subtypes have been largely restricted to one 
over arching construct-outcome. Poor outcome has been associated with ventricular 
enlargement (120,149-151), general GM loss (120,152), and GM volume reductions in 
the posterior cingulate (151), retrosplenial cortices (151), cerebellum (153), frontal lobe 
(120), temporal lobe (28, 152), and thalamus (113). Although many of these studies use 
a correlational design rather than a comparison of good and poor outcome groups, the 
association of poor outcome with numerous structures suggests that a dichotomization 
between outcome groups may successfully associate with brain anatomy. 
Deficit symptoms and Kraepelinian subtypes are highly predictive of clinical 
features of poor outcome (136). It is possible that the "more enduring" nature of deficit 
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symptoms which lead to poorer outcomes increases the likelihood of an association with 
pathophysiology compared with the more state-dependent positive symptoms (37, 154). 
Comparing patients using a Kraepelinian/non-Kraepelinian dichotomy in a series of 
neuroanatomical reports, Mitelman has detected differences in GM volumes and III 
patterns of intra-cortical volume correlations in the Kraepelinian subtype compared with 
the non-Kraepelinian and controls (117, 151, 152, 155, 156) indicating that subtyping by 
outcome is more discriminatory of structural phenotypes than traditional DSM subtyping 
(145). 
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CHAPTER 6: Intercorre/utions between Bruin I/o/limes 
Exploration of the role of brain structure and volume in SZ usually "follow a 
traditional "lesion' model in which changes in one anatomic structure are postulated to 
lead to change in function, symptoms, or outcome .... " (28). A major limitation of this 
approach is the failure to incorporate the dynamic relationships between multiple brain 
regions (28). Theories regarding the etiology of SZ have emphasized the disruption of 
brain networks (38, 40, 110, 124, 157) and recognize that no one region is responsible for 
the illness. Considering there are numerous neural and cognitive networks in the human 
brain, the progression from exploring static groups differences to exploring 
intercorrelations between brain structures within groups is natural. A handful of studies 
have focused specifically on detecting patterns of structural variation in SZ with varying 
success (100, 117, 155, 156, 158-160). 
Considering the 'extent and complexity' of the cortical connections between the 
prefrontal and the temporal lobe structures, Wible (1995) proposed that the variability in 
significant findings for either region may result from the primary dysfunction of the other 
region (158). Selecting a small group of patients (N=15) already shown to have volume 
deficits in left temporal lobe regions, Wible reported no significant differences in 
prefrontal GM volumes between these patients and matched controls. When entered into 
a regression analysis, the authors found that of all the temporal lobe structures measured, 
only the left anterior hippocampal-amygdala complex volume accounted for a significant 
portion of the variance of the left prefrontal cortex (Rsq = .47) and that this association 
was not evident in controls. Although the study sample was relatively small, an inter-
correlation in patients but not controls between two brain regions that are of primary 
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interest III SZ suggests that patients may expenence a dynamic disruption III brain 
morphology that has previously been undetected. 
The heteromodal association cortex (HASC) is a network of higher-order neural 
circuits, which mediate complex cognitive tasks such as working memory, language, and 
attention (161). Primary HASC regions include the dorsolateral prefrontal cortex, 
Broca's motor speech region, the STG and PT, and the inferior parietal lobule (40). 
Abnormalities in the anatomy of primary HASC regions or disruptions in functional 
connectivity may underlie the abnormalities of speech, language, and perception, as well 
as the abnormalities in social and occupational functioning that are cardinal features of 
schizophrenia (40, 161, 162). To explore the pattern of correlations among heteromodal 
regions, Buchanan (2004) quantified the GM volumes of the STG, supramarginal and 
angular gyri, and prefrontal volumes parcellated into four ROIs (100). Using Pearson's 
partial correlations with each pairwise correlation adjusted for all other volumes 
considered, the authors reported 7 significant correlations between HASC regions that 
were similar in patients and controls. In contrast, patients with SZ demonstrated a 
significant positive association between inferior prefrontal and angular volumes and 
between supramarginal and angular volumes in the left hemisphere while controls 
exhibited an inverse association. Although 42 comparisons were made, only 9 
intercorrelations were significant in either patients or controls suggesting that volumes of 
the heteromodal regions may be generally unrelated or that Buchanan's methodology was 
unable to detect such associations. Buchanan's findings are partially consistent with 
Niznikiewicz (2000) finding that volumes of the inferior parietal cortices correlated with 
several prefrontal regions in patients but not in controls (98). 
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In a series of recent reports, Mitelman (117, 155. 156) investigated the potential 
associations between 39 regional brain volumes in 106 patients with schizophrenia and 
42 normal controls. These studies constitute the largest and most extensive assessments 
of volumetric intercorrelations to date. Given the exhaustive detail in each of these 
reports, a summarization of the exact findings would still be lengthy. In general, patients 
showed an "abundance" of stronger than normal positive correlations among temporal, 
frontal and occipital regions as well as a weakening of the inverse correlations between 
the frontal and temporal regions (155). The fact that Mitelman identified numerous 
correlations between Brodmann's areas (the majority of which were positive) indicates 
that widespread volumetric change in the same direction usually occurs in both patients 
and controls. The presence of differences in the pattern of correlations between patients 
and controls supports the theory of disrupted cerebral networks in SZ. Mitelman also 
comments that "anatomical connection between two regions is not a sufticient condition 
for significant inter-correlation of their volumes.... [Instead] the connection must be 
strong enough or an additional superimposed process, such as consistently coordinated 
use of the areas, must be at play" (156). Considering that SZ is theorized to result from 
aberrant connectivity, patterns of regional volumes in patients that deviate from normal 
controls might implicate alternative 'altered' neural networks that either contribute to the 
expression of the disease or strive to compensate for disrupted neural structures. 
Investigating the patterns of regional variation is a necessary step in understanding the 
etiology of SZ. 
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CHAPTER 7: AIMS ond HYPOTHESES 
Independent component analysis (ICA) IS a statistical approach that has the 
potential to identify brain patterns that may differentiate intrinsic subtypes. ICA was 
developed to solve problems similar to the "cocktail party" problem (163) in which 
multiple conversations can obscure attempts to isolate a single conversation. The ICA 
algorithm, assuming independence in time or space, can separate mixed signals (noise) 
into individual sources (voices). Tn reference to structural imaging, ICA allows for the 
decomposition of brain areas into those regions that vary together in GM volume from 
individual to individual (102, 163-165). Each brain is transformed from a three 
dimensional plane into a two dimensional vector and the vectors for each subject are 
arrayed into a matrix. An algorithm is then applied to the matrix to detect elements that 
vary together across subjects (commonalities between vectors) and across the brain areas 
(commonalities between arrays). 
Although this statistical approach is similar to well-known factor analytic 
approaches (e.g., principle components analysis), a major difference between TCA and 
other factor analyses is the statistical theory used to detect patterns. The goal of lCA is to 
detect independence (166). Traditional factor analyses are based on an assumption that 
the data under study are normally (gaussian) distributed. In gaussian distributions, 
uncorrelated components are by definition independent so the factors can be extracted 
successfully. When data are not normally distributed (as traditional methods assume), the 
assumptions of the model are not met and the results become suspect. ICA detects 
independent factors with data that are non-gaussIan usmg alternative mathematical 
assumptions. "ICA could be considered as nongaussian factor analysis, since in factor 
37 
analysis, we are also modeling the data as linear mixtures of some underlying factors" 
(166). I refer you to a technical paper by Hyvarinen (166) for details of the estimation 
process and the algorithm used to decompose the matrix into independent components. 
In addition, ICA requires no a priori knowledge of how regions vary between 
individuals. Thus, using rCA to explore variations in GM segmentation images provides 
a unique opportunity to identify natural groupings of regions and further the 
conceptualization of our anatomical network. 
The use of alternative diagnostic paradigms is a powerful tool for studying this 
specific population but, as of yet, no attempts have been made to subtype patients based 
on brain morphology. Brain anatomy has been explored well enough to conclude that no 
one aberration lies at the root of the illness (167) and that the brain anatomy in patients is 
as varied as the manifestations. Considering the hypothesized role of brain anatomy in 
the etiology of the disease, subtyping patients based on anatomic phenotypes may prove 
to be more successful for identifying valid subtypes and etiologies. Such a method 
provides two meaningful benefits to current practice. First, the subtypes are defined by 
the variation in the population rather than by a somewhat arbitrary clinical definition. 
Second, since aberrations in physiology are hypothesized to underlie the expression of 
symptoms, an association of structural subtypes to clinical features may improve the 
accuracy and validity of a subtype definition. Improved validity can impact both clinical 
and research endeavors. Furthermore, mapping of structural subtypes using larger study 
groups can provide information about each of the goals of psychiatric epidemiology and 
eventually public health's ultimate goal of prevention. 
The HASC hypothesis of schizophrenia postulates that the regions involved in the 
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HASC and their interconnections are disproportionately disrupted (40). This hypothesis 
has gathered support from both structural (discussed previously) and functional data (40). 
Based on previous work by Pearlson and colleagues, I predicted that the regions of 
greatest distinction between patients with schizophrenia and healthy controls will 
predominately involve the primary areas of the heteromodal association cortex. 
An overarching goal of anatomical research in schizophrenia is to characterize 
structural variations so brain morphology can be used in tandem with current clinical 
methods to properly diagnose patients and to reveal underlying pathophysiology. As 
noted by Milev (2003), "in comparison with the abundance of outcome studies using 
demographic and psychopathologic variables, the number of studies that address the 
predictive potential of neuroanatomical measures is [ surprisingly] small" (28). Although 
ICA summarizes the anatomical relationships in the dataset, the subsequent application of 
logistic regression to the independent components extends our knowledge further by 
assessing which components can best differentiate patients with schizophrenia from 
healthy controls. The combination of these two strategies provides a useful way to 
increase understanding of how structural changes in anatomical networks may contribute 
to the disease. 
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CHAPTER B: Doto Anolysis Methods 
Sub/eels.' 
One hundred and thirty three patients with chronic schizophrenia (53 females, 
mean age = 41.6, SD = 12.6, range 19-81) and 133 matched healthy control (HC) subjects 
(69 females, mean age = 41.8, SD = 16.2, range 19-79) were scanned at Johns Hopkins 
University. Patients with schizophrenia or schizoaffective disorder were included based 
on a diagnostic approach that utilized the Structured Clinical Interview for DSM-III-
RlDSM-IV (SCID) (168, 169), direct assessment, family informants, and past medical 
records. Clinical measures of onset, course, symptoms, or cognition were not available 
for the current study. Demographic measures were limited to age and sex of the subject 
at the time of MRI. 
Healthy control subjects were recruited usmg random-digit dialing as part of 
Phase 1 of the Johns Hopkins aging brain and cognition study. All HC subjects were 
evaluated with the same structured interview as the patient group. Subjects were 
excluded if they had a history of DSM-III-RiDSM-IV Axis lor Axis II disorder based on 
the SCID. Exclusion criteria for all samples included a history of overt brain disease, 
mental retardation, head injury with loss of consciousness for greater than 30 minutes, or 
a diagnosis of substance abuse or dependence within the last 12 months. 
MR imaging paramelel:r: 
Whole brain MRIs were obtained on a single 1.5T Signa GE scanner (GE Medical 
Systems, Milwaukee) in the coronal plane using an SPGR (spoiled gradient recall) 3D 
imaging sequence (35msec repeat time, 5msec echo time, 45° flip angle, 1 excitation, 
1.5mm slice thickness, 24cm field of view, and a matrix size of 256 x 256). 
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Optimized ~)o.:rel-ba.fed mOlphometIY.· 
Optimized voxel-based morphometry (VBM) (170) has recently gained favor in 
the field of neuroimaging as a method for comparing localized volumes of brain tissue. 
Unlike ROI studies which traditionally employ manual tracing of regions over a series of 
brain slices, VBM is an automated technique that segments GM, WM, and cerebrospinal 
fluid using structural MRI images for comparison of whole brain or localized measures of 
volume. As an automated process, VBM offers many advantages over manual tracing 
methods by assessing both whole brain and localized regions in one process, increasing 
reliability between studies, and avoiding the time-consuming method of manual tracing 
which also allows for larger sample sizes. In contrast, the automated method requires 
that all structural images be normalized to the same stereotactic space. As a result, VBM 
analyses are less sensitive to shape differences creating a trade-off of validity for the sake 
of reliability. This is of particular relevance to schizophrenia given that these patients are 
more likely to show gross aberrations in brain structure. Nonetheless, an increasing 
number ofVBM studies have confirmed and extended the findings of ROI studies (171). 
MR images were visually inspected for orientation and movement artifact before 
preprocessing. VBM analyses employed the SPM2 toolbox (statistical parametric 
mapping, developed by the Wellcome Institute, London, UK) running in MATLAB (The 
MathWorks, Natick, MA, USA). All images were preprocessed using the optimized 
VBM approach described in detail by Good et al. (47, 170). Particulars relevant to this 
study will be briefly described here. A study-specific anatomical template set consisting 
of a Tl-weighted image and a priori gray, white and cerebrospinal fluid images was 
created from He for the VBM analysis in order to control for intensity differences in MR 
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images due to unique aspects of these data, such as scanner and acquisition parameters. 
To construct the templates (47), images were first reoriented and volumes roughly 
normalized, using a 12-parameter affine model, to the 152 average T 1 MNI (Montreal 
Neurological Institute) template provided as part of the SPM2 package. Normalized 
images were interpolated to voxel dimensions of 1.5mm x I.5mm x 1.5mm and then 
segmented into GM, WM, and CSF using a modified mixture model cluster analysis 
technique, with a correction for image intensity nonuniformity (172). Images were then 
smoothed with an 8mm full-width half-maximum (FWHM) Gaussian kernel and 
averaged across subjects to create Tl, OM, WM and CSF templates. 
For the optimized VBM analysis, all 266 images were segmented in native space 
into GM, WM and CSF compartments and resulting OM images were normalized to the 
customized GM template. Normalization parameters were recorded and applied to the 
raw TI images (170). The resulting images are probabilistic segmentations of GM; the 
addition of the first segmentation step minimizes the number of non-brain voxels 
misclassified as GM (47). Gray matter concentration images (OMC) were then smoothed 
with a 12mm FWHM isotropic Gaussian kernel to compensate for the inexact nature of 
normalization and to ensure statistical validity under parametric assumptions (173). To 
calculate differences in GM volume, the voxel values in the segmented images were 
multiplied by the Jacobian detelminants derived from spatial normalization (47). This 
modulation step preserves the original volume of the segmented image, which is altered 
during the transformation into stereotactic space. It is important to note that GM 
'volumes' as defined in this paper are relative volumes based on the optimized VBM 
modulation step and are not the absolute volumes as calculated by ROI analyses. 
42 
lildependent Component Analvrif: 
Images were processed using the GIFT ICA toolbox (http://catb.sourceforge.net). 
All GM volume images were entered into the ICA toolbox with the HC images entered 
first. Each GM image was converted into a one-dimensional vector and each vector was 
centered to a mean of zero. The 266 vectors were arrayed into a matrix. This subject-by-
gray matter data matrix was decomposed into 30 components with the mixing matrix 
indicating the amount each subject contributed to each component. The number of 
components was determined using the order estimation tool in the GIFT toolbox (174). 
Output images and mixing matrix columns for each component were scaled to unit 
standard deviation. 
Regrefsion Ana(yses 
After estimating components, the mlxmg matrix parameters (i.e., component 
loading scores) for each subject were extracted to SAS v9.1. Since both diagnostic 
groups were entered into the same ICA matrix, we first compared the diagnostic groups 
for significant differences in component loading scores using an independent samples t-
test. This step aimed to reduce the number of components of interest and to limit further 
analyses to components where the patient and control groups differed in the magnitude to 
which they loaded on each component. To test the association of each remaining 
component with the outcome variable, component loadings that were significantly 
diflerent by diagnostic group at p<0.05 using a t-test were entered into a logistic 
regression. 
Since the outcome variable is dichotomous, binary logistic regression was used 
1) to assess which of the independent components significantly predicted diagnostic 
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group, 2) to rank the relative importance of each predictor, and 3) to determine the 
amount of variance in the actual diagnoses that can be explained by the observed 
components. Logistic regression uses the maximum likelihood estimation after first 
transforming the outcome variable into a logit variable (175). Logit is the natural log of 
the odds of the outcome occurring or not occurring. Discriminant function analyses 
could also have been used to test the ability of these components to correctly classify 
subjects' diagnosis. In this instance, logistic regression was preferred because it provides 
the coefficient for each component which allows for the reporting of odds ratios with 
confidence intervals for each component's association with the outcome measure (176). 
Yisualizatiol1 .. 
For visualization of group differences identified from logistic regression analyses, 
voxels for significant components which contributed to the component at a value of 
IZI> 3.1 were superimposed onto SPM2' s spatially normalized template brain. 
Coordinates were transformed from the MNI coordinate system to the coordinates of the 
standard space of Talairach and Tournoux (177) using a MATLAB conversion program 
written by Matthew Brett (MRC Cognition and Brain Sciences Unit, Cambridge, 
England). Once converted, Talairach coordinates were entered into the Talairach 
Daemon (178) for localization. 
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CHAPTER g: RESULTS 
Previous structural MRI studies compare patients and control groups for absolute 
or relative differences between volumes at a single location in the brain. Although this 
approach may be useful in the identification of brain regions involved in the expression 
of the disease for the entire group, it provides minimal information about the natural 
patterns of brain volumes within groups. ICA decomposes the GM volume variation 
from the large subject-by-voxel matrix into a smaller subject-by-component matrix. Each 
component represents a distinct GM volume pattern extracted from the dataset. The 
component loading score is a quantitative measure of how much each subject correlates 
with that component/GM volume pattern. Thus, ICA is in a position to detect natural 
constellations of brain volumes within groups of subjects which may reflect valid neural 
networks that have been poorly detected using correlational or factor analyses (100, 117, 
122, 155, 156, 159). 
Thirty components were estimated using ICA. Each component was displayed 
over a single subject brain image in the GIFT toolbox and visually inspected to identify 
the major brain regions involved in each component. The primary brain region detected 
by each component is listed in table 1. Eight components displayed patterns that were 
suggestive of artifact, such as ringing around the edges of the cerebrum. Three 
components represented the areas of the ventricles where no GM tissue was expected. 
These eleven components may have been detecting artifactual variation in brain volume 
introduced during the image normalization process. Artifact and reduced variability are 
both limitations incurred by the normalization process that have been acknowledged and 
accepted by the neuroimaging community as an acceptable trade-off for increased 
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automation. Since brain size and shape are of particular interest in this study, areas of the 
brain that are more susceptible to artifactual volume (GM bordering ventricles) are 
interpreted with caution since patients with SZ are more likely to have gross structural 
aberrations which require more extensive reshaping during normalization. 
T-test 
Of the 30 components estimated using lCA, a comparison of the patient group to 
the control group using an independent samples t-test identified 11 components where 
subjects' component loading scores were significantly different by diagnostic group. 
Only one of the 11 components previously considered to be artifictual was found to be 
significant. Component 30 was significant at p<0.05 with mean SZ scores greater than 
HC scores. Five of the 11 significant components had mean component loadings that 
were greater in the HC group. The remaining six components had mean component 
loadings that were greater in the SZ group. 
Regression ana[vres 
To estimate the potential for independent components to predict diagnostic group, 
a multiple logistic regression was run with the 11 components above as the independent 
variables and with diagnostic group as the outcome measure. Since this analysis is 
exploratory rather than hypothesis driven, three entry methods (forward conditional, 
backward conditional, and stepwise) were used to assess the model. Each method 
resulted in the same six components signiticant at p<O.05 with the full model significant 
at p<O.OOOI (table 2). The Hosmer-Lemeshow goodness of fit test (175) was not 
significant (X2 =3.05, df=8, p=O.93) indicating that there is no difference between the 
outcomes observed and the outcomes predicted by the six variables. 
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Linear regression uses the R-square statistic to quantify the amount of variance in 
the outcome variable that is accounted for by the predictor variables. In logistic 
regression, the variance of a dichotomous outcome measure is dependent on its frequency 
distribution. Since the distribution can vary between samples, there is no accurate 
measure of variance for comparison between models. Despite this, several alternatives 
have been proposed that seek to adjust for the limitations of the logistic model (175). Of 
these alternatives, the Nagelkerke (1991) measure of variance is the most reported (175). 
In this study, the Nagelkerke R-square estimates that approximately 34.82% of the 
variation in diagnosis is explained by these six components. 
Assessing the accuracy of a predictive model such as this one is a critical to 
evaluating its utility. ROC curves provide a standardized way of quantifying the trade-
off between specificity and sensitivity and provide an overall measure of the ability of 
these components to predict a diagnosis of SZ. The curves are also visually intuitive for 
the interpretation of predictive accuracy. The overall accuracy of this model in correctly 
discriminating diagnostic group was 80.5% (using a predicted probability of 0.5 or 
greater) and is represented by the area under the curve (AUC) (figure 1). The maximum 
percentage of individuals who were correctly classified by diagnostic group was 73.3, 
with a sensitivity of 70.7% and a specificity of 75.9% (table 3). In this sample, the 
positive predictive value of the 6 components was 74.6% and the negative predictive 
value was 72.1 % (table 3). However, in this study there are equal numbers of patients 
and controls. In the general population, prevalence of SZ is less than 1 %. In order for 
the "true" predictive values of these components to be evaluated, the analyses would need 
to be repeated with a sample that reflects the actual disease prevalence (176) (see table 3, 
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panel B). 
Anatom.)/ if the independent Components 
Five components represented heteromodal association cortex areas and one 
component represented sub-cortical thalamic areas. Three components represented areas 
where GM volumes were relatively greater in HC than patients (table 4, figure 2) while 
the remaining three represented regions where GM was relatively greater in 
schizophrenia (table 5, figure 3). The six components will subsequently be referred to by 
the anatomical regions they represent and are listed here in order of their respective 
contributions to the prediction of diagnostic group. 
Component 24: He Parietal 
The strongest association with diagnostic group was component 24. This 
component consisted of bilateral parietal GM volume that was greater in HC than 
schizophrenia (blue in figure 2). The GM differences were predominately sub-gyral and 
located medial to the right IPL in the dorsal portion but became bilateral as the GM 
difference was tracked into the temporo-parietal junction. Although the "HC parietal" 
component extended into the temporal gyri, its regions were posterior to the STG regions 
expressed in the "HC temporal" component (discussed next). This component accounted 
for approximately 11.4% of the variation in diagnostic according to the Nagelkerke R-
square statistic. 
Component 13: HC Temporal 
The most extensive contiguous regIOn of GM differences between diagnostic 
groups was found in the region of the STG (red in figure 2) with healthy controls having 
more GM than patients with schizophrenia. These GM differences were notably 
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constrained to the STG and its medial counterparts, the transverse temporal gyrus and 
insula, suggesting a clear distinction between these structures (as a single component) 
and the rest of the temporal lobe. The GM differences were slightly lateralized (R>L) 
posteriorly in the PT and became increasingly lateralized as the gyrus descended toward 
the temporal pole. The larger STG and its lateralization are consistent with previous 
findings. This component accounted for an additional 7% of the variation in diagnostic 
group. 
Component 27: SZ Thalamic/Hippocampal 
Component 27 consisted of substantially larger GM in schizophrenia patients in 
the thalamus, hippocampi and parahippocampal gyri, and medial temporal regions (green 
in figure 3). The thalamic increases in schizophrenia were localized to the medial, 
anterior, and ventral nuclei and hypothalamus, but did not extend into the lateral thalamic 
areas. Both hippocampi were larger in schizophrenia and this effect extended focally 
along the parahippocampal gyri. The thalamic and hippocampal regions covaried with 
two bilateral nodes located medial to the temporal lobe (BA 21, 22). This component 
accounted for an additional 7% of the variation in diagnostic group. 
Component 25: HC Frontal/Occipital 
This component represented greater GM volumes in HC compared with 
schizophrenia and was expressed bilaterally in the middle frontal gyri, extending 
medially into sub-gyral areas (green in figure 2). The isolated region along the middle 
frontal gyrus covaried with GM volumes in the posterior regions of the STG bilaterally, 
the middle temporal-middle occipital junction, and the primary visual areas (BA 17, 18). 
This component accounted for an additional 2.5% of the variation in diagnosis. 
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Component 2: SZ Parietal 
In the parietal lobe, patient with schizophrenia also showed greater volumes 
bilaterally in portions of the IPL (red in figure 3). The increases in schizophrenia patients 
were less medial than those in the "HC Parietal" component and did not extend ventrally 
into the STG or medial temporal areas. The regions comprising this component were 
more extensive in the right hemisphere. Furthermore, the IPL regions in this component 
showed a covariance with a posterior section of the medial temporal gyrus bilaterally and 
the lingual areas (BA 17, 18). This component accounted for an additional 6% of the 
variation in diagnostic group. 
Component 3: SZ Frontal/Temporal 
While the majority of components comprised focal GM differences, this 
component consisted of several regions scattered throughout the brain (blue in figure 3). 
Areas in this component included discrete nodes in the superior, middle, and medial 
frontal gyri (along the GM/WM border), the temporo-parietal junction, and the posterior 
STG. The varied location of these small nodes likely contributed to the diminished 
significance of this component in the regression model. However, the correlated regions 
all represent areas of the HASC and are suggestive of a GM volume basis to the HASC 
network. This component accounted for an additional 1.5% of the variation in diagnosis. 
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CHAPTER I(j: IJISCOSSION 
Unlike traditional GLM studies which test for a static, absolute difference in 
volume at a given voxel between diagnostic groups, ICA explores patterns of variation 
that occur within and between subjects. Each component extracted using ICA represents 
a set of brain regions that covary in a particular way between subjects (as indicated by the 
mixing matrix parameters). In this study, patients with schizophrenia and healthy 
controls were analyzed as a single dataset to allow the extraction of natural variations in 
structure. Significant components do not represent absolute GM volume differences but 
represent areas of GM volume where the individuals of one diagnostic group positively 
correlate with the given GM volume pattern (on average) while the subjects in the other 
diagnostic group negatively correlate with the component. 
Regressioll Alla{yscr 
By itself, ICA provides a decomposition of data into a smaller set of structural 
patterns. In order to identify group differences, significance testing was performed on the 
component loading scores. Since both diagnostic groups were included in our model, 
testing for group differences using component loadings identified regions of the brain 
where one diagnostic group had significantly different GM patterns than the other group. 
A binary multiple logistic regression of the component loadings identified six 
components that were highly predictive of diagnostic group: overall the model was able 
to correctly discriminate diagnostic group 80.5 percent of the time. With further 
research, anatomical differences in GM volumes such as those identified using lCA 
might be capable of predicting diagnosis on an individual level. 
Predictability 
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Although this model appears to be a good predictor of diagnostic group based on 
the sample at hand, the utility of this model should be interpreted with caution. Briefly 
discussed in chapter nine, under real world conditions, this model is unlikely to retain its 
rather high predictive ability. This is because the samples included in the study are not 
fully generalizable to their respective populations (176). 
The measures of predictive value are based on the proportion of subjects who do 
or do not have the disease. The study prevalence of disease positive subjects 
substantially influences measures of predictive value. For example, positive predictive 
value is a ratio of true positives to all positives. In this study, 94 out of 126 subjects were 
accurately predicted to be positive (74.6%) with a 1: 1 ratio of patients to controls. In a 
sample where disease-free subjects are much more common, say a ratio of 1:9 for 
patients to controls, the sensitivity and specificity of the test remain the same but the 
predictive ability of the test changes (table 3, panel B). When the prevalence of disease 
individuals is substantially lower than the disease free individuals, the ability to predict a 
positive status is reduced while predictive ability of negative status is greatly increased. 
Prevalence of SZ is estimated to be less than 1 % of the popUlation (less than a 1: I 00 ratio 
of SZ to non-SZ) suggesting the PPV of these 6 components will be remarkably lower 
while the NPV will be close to 100%. One additional point to consider is the context in 
which a test such as this one will be applied. Although prevalence is very low for SZ in 
the general population, the proportion of individuals who present for diagnosis upon 
whom this test may be used will have a much higher ratio of SZ to non-SZ. Thus, in 
actual applied settings. the low prevalence of SZ may be less of an issue. 
Spectrum refers to the sampling of the population. Although the patients in this 
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study fall along a wide-spectrum of age, sex, and chronicity, the fact that these patients 
participated in a research study indicates that they are relatively high functioning and able 
to provide informed consent. In addition, patients with schizoaffective diagnoses were 
included in the sample. These factors are likely to impact the sensitivity of this model in 
SZ only populations. The same effect is seen on specificity when the comparison 
population does not adequately reflect the real world population. Neuroimaging studies 
routinely require control subjects to be psychiatrically and physically healthy. Not only 
does this make the control sample less generalizable to the real world population, but it 
undermines the nature of specificity. The goal of specificity is to distinguish one type of 
illness from another. Thus, as an example for this study, a good control group would 
include patients with non-SZ psychiatric illnesses, relatives of patients with SZ, and 
persons that demonstrate similar symptoms or cognitive deficits but for reasons other 
than SZ. Given that the nature of this study was exploratory, wide spectrum control 
populations may mask the detection of an effect and are perhaps premature in this 
context. With more refined hypotheses and meaningful applications, the dependence on 
wide-spectrum study groups reiterates the importance of large-scale epidemiological 
studies of brain structure, clinical presentation, and genotypes in the search for 
anatomical predictors of schizophrenia. 
Bias, on the other hand, is less of an issue in this study. Bias can falsely inflate 
sensitivity and specificity when the examiner is aware of the test result during diagnosis 
or is aware of diagnosis when evaluating a test result. Any subjectivity in this study is 
limited to diagnosis of the subject prior to imaging. Since a diagnosis is required for 
inclusion in the study, all diagnoses are unaffected by the imaging results. Alternatively, 
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the brain scans are evaluated by an automated, bias free process during both VBM and 
lCA. In this study, experimenter bias is completely independent of the predictor 
variables and is not likely to impact this study's predictive efficacy. The impact of bias 
will reemerge in these types of studies, however, should brain morphology become part 
of the diagnostic workup for schizophrenia. 
Strue/ura! D(jJerences 
The application of ICA to detect structural GM volume differences between 
healthy controls and patients with schizophrenia successfully identified six components 
that diflerentiated diagnosis. Five of the six components corresponded to areas of the 
heteromodal association cortex that have been implicated in the disorder; the remaining 
component is hypothesized to sub serve the HASC network. Our findings of smaller GM 
volumes in the patient group in the STG, IPL, and prefrontal regions are consistent with 
past research (l00). 
The ability for TCA to detect discrete regions of variation is particularly valuable. 
The "HC Temporal" component indicates that healthy controls consistently possess more 
GM volume bilaterally in a large, continuous region of the temporal lobe that included 
the STG, PT, transverse temporal gyrus, and insula. Restriction of the volume disparities 
between groups to this temporal region suggests that GM volumes in these areas, but not 
in the middle or inferior temporal regions, were a discriminating anatomical difference 
between patients and controls and is consistent with previous reports of selective 
reductions in the STG (61, 77, 155). A similar effect was seen with the "HC Parietal" 
component with relative increases in controls bilaterally in the medial regions of the 
inferior parietal lobule. These two components suggest that STG and lPL structures are 
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each internally consistent m volumetric changes. This uniformity may underlie the 
power of these two components in this regression model. These two components alone 
correctly classified 68.8% of the individual diagnoses. 
The remaining four components demonstrated several inter-correlations in volume 
change throughout the brain. Notably, both the "He Frontal/occipital" and "SZ 
Frontal/temporal" components revealed several non-prefrontal GM changes that covaried 
with the prefrontal volumes. This is consistent with Mitelman's (2005) reports of inter-
correlations between prefrontal volumes and temporal and occipital volumes in patterns 
that ditJered between patients and controls (156). Although it is not possible to 
demonstrate connectivity between GM regions based on volume correlations, the 
association in volume change between these regions implies that a search for abnormal 
connectivity may be fruitful. In addition, the focal GM differences found in these two 
components may explain the greater success of parcellation studies over whole lobe 
measurements in detecting anatomical differences. Although past research has mainly 
detected differences in the inferior and orbital frontal gyri, our findings of GM deficits in 
schizophrenia in the middle frontal gyrus were consistent with Gur (179) and 
Goldstein(97). 
Relative mcreases m GM volume in the IPL were evident in both diagnostic 
groups. In the "He parietal" component, controls had greater IPL volumes in the right 
superior parietal lobule and angular gyrus and bilaterally in the supramarginal gyrus and 
posterior portions of the temporal gyri. In the "SZ Parietal" component, patients 
exhibited greater GM volumes posterior to and more lateral than the regions in the "He 
temporal" component and did not extend into temporal areas. Although volumetric 
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studies of the IPL in schizophrenia are limited, GM reductions in schizophrenia were 
consistent with previous reports of volume reductions in the angular and supramarginal 
gyri in schizophrenia (85, 97, 98, 101). Different but adjacent regions in the parietal 
cortex that showed consistent volumetric change within subject groups suggests that GM 
volumes in the parietal lobe may be not be wholly decreased in patients. Instead, patients 
may display altered morphology that occurs inconsistently between patients. Since ICA is 
sensitive to variations common among a subset of the population group, it is possible to 
extract components representing GM variations that were not detectable using traditional 
VBM approaches. Similar IPL volume reductions in patients were found with joint ICA 
(iICA), supporting a potential role of the IPL in the expression of the disease (102, 165). 
In the jlCA study as in this study, the smaller GM volumes in patients versus controls 
were located medially in the GM regions. It is also possible that reductions of GM in 
patients in this region represent increases in WM. Future studies should investigate GM-
WM volume interactions using ICA. 
The patient group showed the most intense GM increases in the thalamic and 
hippocampal regions. MRI studies of thalamic volumes in schizophrenia generally report 
reductions in patients( 57, 180) or no significant differences between patients and 
controls. In our study, ICA detected increases in thalamic and hypothalamic volumes for 
patients that correlated with GM decreases in controls. Since ICA detects variations in 
volumes common within and between individual subjects rather than absolute volume 
differences between groups, our results may not be fully comparable to those reported 
using standard volumetric methods. The "schizophrenia thalamic\parahipp" component 
included sizable GM increases in the parahippocampal gyri and the medial portions of the 
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middle and superior temporal gyri (BA 21, 22) as well. 
As an automated procedure, VBM may incorrectly segment voxels along the 
perimeter of the ventricles as OM (47, 170). The location of the thalamic structures at the 
base of the ventricles may heighten the likelihood that these structures are misclassified 
and OM volumes are spurious. Although this is possible, the specificity of the 
misclassification to one diagnostic group is unlikely, suggesting that anatomical 
differences detected in this region are rcal, albeit misclassified. Non-automated analyses 
of this region may determine the validity of the VBM segmentation and localization of 
diagnostic group differences to thalamic structures. Alternatively, ICA may serve as a 
powerful tool for exposing underlying variations specific to overlapping subgroups of a 
population that are not detectable using univariate methods. Further research on 
volumetric variations in the thalamus is recommended. 
Conclusions 
The use of ICA to explore OM segmentation allowed for the identification of 
natural groupings of regions that showed disparate volumetric variations between 
schizophrenia and HC. These findings agree with previous reports on OM differences in 
schizophrenia. Our study provides support for the HASC theory of schizophrenia-five 
of the six components that significantly predicted diagnostic groups were composed of 
regions of the HASC. An estimated 34.8% of the variation in diagnosis was accounted for 
by OM volumes in these six components, which supports a substantial role for structural 
abnormalities in the expression of schizophrenia. The separation of these regions into 
different components suggests that there are complex and regionally specific structural 
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changes occurring in schizophrenia. This may explain variability in previous findings 
because most methods have simply identified volumetric changes from HC without 
grouping together regions which exhibit similar changes. 
The application of ICA to structural brain images creates new opportunities to 
assess variations in regional brain morphology. Comparisons of the independent regional 
variations between diagnostic groups may reveal differences not detectable using 
traditional univariate methods and may provide new insight into the complex structural 
changes occurring in mental illness. However, this is only a first step in the overall goal 
of reevaluating the utility of the current diagnostic systems. Future research investigating 
the anatomical phenotypes should consider the aims discussed in this thesis in an effort to 
further our understanding of the etiologies and construct of schizophrenia. 
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Table 1: Each ICA component and the primary region represented by the component. Component loading scores were 
grouped by diagnosis and descriptive statistics for each group are listed. Results of each independent samples t-test are 
listed in the final columns. * = p < 0.05, ** = P < 0.01 
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27 -0.195 . halamllS aoo J.ledialTemporal Lobe 
I .. ·········· .~~.··:··: .. ;· .. · .. ······:··J~i~:~.:·.~:~~ .. ~i~81.L0t>e ... ~inQln.Q.. ... . ............................................. 1.. 0.0 31 
29 i iArtilld: Occipital Pole Ringing -0.096 
........... ~ ········t·································· .... · ............................ , ........................................................... . 
30 ,Artiflld: Posterior Lateral Ventrides -0.147 , 
0.195 -2.850 ; -2.430 
0.963 
1.002 
0.993 
1008 
1.009 
0.899 
1039 
1.001 
0.921 
0.926 
0.988 
0.096 
0146 
I' 'I' 1.060 
-0.031 ·~~~~T~~;~~ ~:~r ~::~ ...... ~.:~l ~.~~~ 
-2.390+-2450 2.640 i · 2.550· ···1.0181. 0.963 
0.083 . 0.090 
•• ,ij. •• 
0.087 i 0.087 
...... 
0.086 . 0.080 
0.087.! 0.080 
0.088 : 0.086 
...... 
0.078 : 0.092 
0.085 .. ; .. 0.089 
0.091 
0.088 
0.082 
0083 
0.372 
t-test for E wa1itv of Moons 
Moon 
II' Sig. 
264 
-3.745: 264 
o 710 
0000 
0.005 
-1.460 
3.208 
-2.291 
-1.937 
-0.937 
-2.411 
264 
264 
264 
264 
264 
SE of 
Table 2: Regression coefficents and signfICance levels in order of effect size_ 
Component Brain Region B S.E. Wald Sig. EXP{B) 
3 SZ fro ntal/tempora I 0_306 0_155 3_918 0_048 1_359 
2 SZ parietal 0_543 0_156 12_147 0_000 1_721 
25 He frontal/occipital -0.366 0_152 5_819 0_016 0_694 
27 SZ thalamidhippocampal 0_591 0_160 13_664 0_000 1.805 
13 He temporal -0_612 0_156 15_370 0_000 0_542 
24 He parietal -0_723 0_167 18_748 0_000 0_485 
Table 3: Observed diagnoses compared to the diagnoses predicted by the 
regression model. Panel A provides the predictive values for this study sample in 
which there is a 1:1 ratio of patients to controls_ Green represents the number of 
subjects correctly classified by the model. Red represents the subjects that were 
incorrectly classified_ Overall, the regression model in this study accurately 
classified 195 (73_3%) of the 266 subjects_ Panel B provides the predictive value of 
this model if the study sample reflected a low prevalence of patients (a ratio of 1 :9), 
as would be the case when applied as a screening tool. PPV = positive predictive 
value_ NPV = negative predictive value_ 
A. Observed 
SZ He 
(N=133) (N=133) 
94 32 PPV=74.6% -g SZ U (N=126) :g He r------+------i 
Q: (N=140) 39 101 
'--------'-------' 
NPV=72.1% 
Sensitivity Specificity 
=70.7% =75.9% 
B. Observed 
SZ He 
(N=26) (N=240) 
-g sz I ~ (N=77) 
r----+---------1 
-g He 
Q: (N=189) '--__ 7_-'--_1_82_-' 
58 19 PPV=24.7% 
NPV=96.3% 
Sensitivity Specificity 
=73.1% =75.8% 
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Table 4: Talairach labels of regions where healthy controls have greater GM volumes 
than patients. Voxels above the threshold in figure 2 were converted from Montreal 
Neurological Institute (MNI) coordinates to Talairach coordinates and entered into a 
database to provide anatomic and functional labels for the left (L) and right (R) 
hemispheres. The volume of voxels in each area is provided in cubic centimeters (cc). 
Within each area, the maximum Z value and its coordinate are provided. 
Comp13: Temporal, HC > 
SZ 
Superior Temporal Gyrus 
Precentral Gyrus 
Transverse Temporal Gyrus 
Insula 
Postcentral Gyrus 
* 
Middle Temporal Gyrus 
Inferior Frontal Gyrus 
Inferior Parietal Lobule 
Sub-Gyral 
Comp24: Parietal, HC > SZ 
Superior Temporal Gyrus 
Supramarginal Gyrus 
Sub-Gyral 
Middle Temporal Gyrus 
Inferior Parietal Lobule 
Angular Gyrus 
Precuneus 
Insula 
Superior Parietal Lobule 
Extra-Nuclear 
Postcentral Gyrus 
Middle Frontal Gyrus 
Precentral Gyrus 
Comp25: Frontal, HC > SZ 
Sub-Gyral 
Middle Frontal Gyrus 
Lingual Gyrus 
* 
Middle Temporal Gyrus 
Middle Occipital Gyrus 
Superior Temporal Gyrus 
Inferior Frontal Gyrus 
Insula 
Brodmann 
Area 
22, 42,41 , 13, 
38, 29,21 
6, 13, 43, 44 
41 , 42 
13, 40,29 
40, 43 
Optic Tract 
21,38 
47 
40 
Brodmann 
Area 
39,22,13 
40 
39,22, 19 
40 
7 
13 
7 
1, 3, 2 
6 
6, 4 
Brodmann 
Area 
9, 46 
18, 17 
39 
19 
39,13,41 
13 
R: Max-Z (x, y, L: Max-Z (x, y, 
R: cc L: cc z) z) 
11 .3 5.8 7.6(-50,-6 ,3) 5.2(50,-20,9) 
1.4 
0.9 
3.7 
2.2 
0.4 
0.7 
1.6 
0.7 
0.4 
0.3 7.6(-50,-8,6) 4.5(48,-17,12) 
1.4 6.4(-48,-17,12) 5.2(45,-26,12) 
2.1 6.3(-45,-14,9) 4.7(42,-28,15) 
0.3 6.0(-56,-23,15) 3.8(56,-25,15) 
0.1 
o 
o 
0.1 
o 
5.3(-48,0,3) 3.3(0,-17,4) 
4.7(-53,0,-8) n.s. 
4.6(-48,14,-6) n.s. 
4.4(-59,-28,24) 3.4(53,-37,24) 
4.2(-48,-11,14) n.s. 
R: cc L: cc R: Max-Z (x, y, L: Max-Z (x, y, 
1.8 
2.1 
7.3 
0.9 
1.4 
0.6 
0.5 
0.2 
0.1 
0.3 
o 
0.2 
o 
z) z) 
0.6 12.4(-39,-51 ,25) 6.1 (39,-54,19) 
0.2 12.1 (-39,-51 ,27) 5.9(36,-54,28) 
4 11 .7(-36,-51 ,25) 8.2(33,-54,22) 
0.6 10.8(-36,-54,25) 8.1(36,-54,22) 
o 9.9( -42,-48,25) 3.3(36,-45,27) 
9.9(-39,-54,30) n.s. o 
0.2 7.0(-27,-47,44) 4.0(21 ,-48,30) 
5.9(-39,-43,21) n.s. 
5.8(-27,-50,44) n.s. 
o 
o 
0.3 5.3(-33,-46,19) 5.3(30,-49,19) 
0.7 n.s. 3.8(45,-26,62) 
o 3.5(-30,28,32) n.s. 
0.2 n.s. 3.3(42,-11 ,61) 
R: Max-Z (x, y, L: Max-Z (x, y, 
z) z) R: cc L: cc 
2.5 
2.8 
1.6 
0. 1 
0.6 
1.2 
0.8 
0.1 
0.2 
3 7.5(-36,24,24) 8.8(36,21 ,21) 
0.9 7.4(-39,24,24) 6.5(36,22,27) 
1.9 6.9(0,-91 ,-8) 7.3(3,-91 ,-8) 
0.5 4.8(-3,-88,-11) 6.9(3,-91 ,-11) 
0.2 5.4(-42,-72,12) 4.3(48,-43,8) 
1 5.4(-39,-75,9) 4.6(36,-78,12) 
2.2 4.2(-48,-37,13) 5.4(48,-43,10) 
4.3(-33,10,27) n.s. 
3.9(-48,-40,19) n.s. 
o 
o 
61 
Table 5: Talairach labels for regions where patients with schizophrenia have greater r 
GM volumes than healthy controls. Voxels above the threshold in figure 3 were 
converted from MNI to Talairach coordinates and entered into a database to provide ~ 
anatomic and functional labels for the left (L) and right (R) hemispheres. The volume of f 
activated voxels in each area is provided in cubic centimeters (cc). Within each area, 
the maximum Z value and its coordinate are provided . 
Comp2: Parietal, SZ > HC 
Sub-Gyral 
Inferior Parietal Lobule 
Angular Gyrus 
Supramarginal Gyrus 
Superior Parietal Lobule 
Precuneus 
Lingual Gyrus 
Middle Temporal Gyrus 
* 
Cuneus 
Middle Frontal Gyrus 
Middle Occipital Gyrus 
Fusiform Gyrus 
Inferior Temporal Gyrus 
Comp3: FrontallTemporal 
SZ>HC 
Sub-Gyral 
Superior Frontal Gyrus 
Middle Frontal Gyrus 
Middle Occipital Gyrus 
Med ial Frontal Gyrus 
Middle Temporal Gyrus 
Superior Temporal Gyrus 
Supramarginal Gyrus 
Inferior Frontal Gyrus 
Cingulate Gyrus 
Precentral Gyrus 
Inferior Parietal Lobule 
Comp27: Thalamic/Hippo 
SZ>HC 
Extra-Nuclear 
Thalamus 
Sub-Gyral 
Middle Temporal Gyrus 
Lateral Ventricle 
Superior Temporal Gyrus 
Uncus 
Parah ippocampal Gyrus 
Middle Occipital Gyrus 
Anterior Cingulate 
Inferior Parietal Lobule 
Inferior Frontal Gyrus 
Brodmann 
Area 
40, 39, 7 
39 
7 
19, 39, 7 
17,1 8 
19, 39,22, 21 
17 
6 
37,20, 36 
37 
Brodmann 
Area 
6 
10, 9 
9, 10, 6, 11 
19 
10, 6,9 
39, 19 
22 , 39 
32 
9 
Brodmann 
Area 
Optic Tract 
21 , 22 
22, 21, 38 
20,28 
35, 36, 28, 
30, Amygd. 
19 
25 
40 
47 
R: cc L: cc R: Max-Z (x, y, 
z) 
1.6 
2.9 
0.6 
0.4 
0.5 
0.5 
1.2 
1.9 
° 0.2 
0.3 
° 0.9 
0.1 
0.5 12.4(-33,-53,39) 
0.9 11.7(-36,-56,39) 
0.2 10.8(-33,-54,36) 
° 
9.3(-33,-51 ,36) 
0.2 7.9(-30,-56,44) 
1 6.6( -36,-62,36) 
0.5 4.9(-3,-90,-3) 
0.9 4.7(-45,-63,14) 
0.4 4.3(0,-85,-1) 
0.2 4.3( -3,-93,0) 
° 0.1 
° 
° 
4.4( -33,5,44) 
n.s. 
3.5( -42,-50,-15) 
3.3( -45,-42,-18) 
R: cc L: cc R: Max-Z (x, y, 
z) 
2 
1.9 
1.8 
1 .1 
1 
0.7 
1.1 
0.1 
0.2 
0.2 
0.2 
0.1 
1.5 5.4(-21 ,-1,47) 
1.2 5.4(-27,52,0) 
1.4 5.8(-27,33,26) 
0.1 5.4(-36,-75,1 5) 
0.5 5.3( -24,36,26) 
0.4 5.3(-36,-75,18) 
0.4 5.2(-45,-51 ,19) 
° 
4.8(-45,-51,22) 
0.1 4.2(-39,5,33) 
4.3(-18,2,47) 
4.2(-39,5,36) 
3.5(-42,-48,22) 
° 
° 
° R: cc L: cc R: Max-Z (x, y, 
z) 
2.2 
0.4 
0.3 
0.4 
° 
1.2 6.7(-3,-17,1) 
1.8 7 .O( -3,-14,3) 
1.3 4.6(-45,-32,2) 
1.2 4.4( -48,-32,2) 
0.3 5.2( -3 ,-3,3) 
0.9 4.0( -48,-32,4) 
0.4 n.s. 
2.2 3.2 3.8(-24,-18,-14) 
0.1 ° 4.1(-30,-78,20) 
0.3 ° 4.1(0,2,-10) 
0.1 0.1 3.7(-36,-45,38) 
° 0.2 n.s. 
L: Max-Z (x, y, z) 
7.3(33,-59,39) 
6.8(36,-59,39) 
6.3(33,-59,36) 
n.s. 
4.8(33,-59,44 ) 
6.8(33,-62,39) 
4.9(0,-90,-3) 
4.8(42,-66,17) 
4.7(0,-93,-3) 
4.4(0,-93,0) 
n.s. 
4.2(39,-69,17) 
n.s. 
n.s. 
L: Max-Z (x, y, z) 
6.1 (24,50,3) 
6.0(27,47,6) 
5.9(27,50,3) 
3.3(33,-78,15) 
4.5(24,44,6) 
3.7(48,-55,11 ) 
4.1 (45,-57,17) 
n.s. 
4.4(36,10,27) 
n.s. 
n.s. 
n.s. 
L: Max-Z (x, y, z) 
7.5(0,-14,3) 
6.4(3,-14,3) 
5.8(48,-32,-1 ) 
5.7(48,-35,2) 
4.6(3,-3,3) 
5.1(48,-26,-1) 
4.9(30,-16,-27) 
4.4(30,-16,-24 ) 
3.2(27,-81 ,21 ) 
n.s. 
3.7(36,-48,38) 
3.6(42,14,-11 ) 
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Figure 1: Receiver Operator Characteristic (ROC) curve 
based on the predicted probabilities of the 6 component 
model. The area under the curve (AUC) indicates that the 
overall accuracy of the model is 80.5%. 
1 .0 
0 .8 
AUC =0.805 
0.4 
r~ 
0.2 
0 .0 -F----..-------,,----..----r------r---' 
0.0 0 .2 0.4 0.6 0 .8 1 .0 
1 - Specificity 
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Figure 2: Of the six components that significantly predicted diagnosis, the three 
components where GM volumes were relatively greater in controls are displayed 
here. Blobs represent voxels above the threshold of Z>13.11 . Red = He 
temporal component, blue = He parietal component, green = He frontal-occipital 
component. 
64 
Figure 3: Of the six components that significantly predicted diagnosis, the three 
components where GM volumes were relatively greater in patients are displayed 
here. Blobs represent voxels above the threshold of Z>13.11. Red = SZ parietal 
component, blue = SZ frontal-temporal component, green = SZ thalamic 
component. 
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